PF-Atlas › Clinical Trials › NCT02788474
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
nintedanib · Phase 4
Registry ID
NCT02788474
Phase
Phase 4
Status
Completed
Drug / intervention
nintedanib
Sponsor
Boehringer Ingelheim
Start
2016-06-09
Enrollment
347
Locations
86
About this trial
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02788474 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.